PURPOSE: To evaluate pharmacokinetics (PK) and safety of fezolinetant after single-dose and multiple-dose administration of 15, 30, and 60 mg in healthy Chinese women. PATIENTS AND METHODS: This was a fixed-sequence crossover study in 16 healthy Chinese female subjects, 18-45 years old. All received single doses of fezolinetant 15 mg, 30 mg or 60 mg with a 3-day washout. From Day 10, subjects received multiple doses of 30 mg fezolinetant once-daily for 7 days. PK parameters were obtained during the single- and multiple-dose periods. Safety assessments were based on adverse events, vital signs, and laboratory tests. RESULTS: Fezolinetant exhibited rapid absorption, with median time of the maximum concentration (t CONCLUSION: Linear PK was confirmed within the dose range of 15 to 60 mg in healthy Chinese women.